A list of commonly used measurement tools for psoriasis management and clinical trials.
General
A simple 10-question validated questionnaire that has been used in over 40 different skin conditions in over 80 countries and is available in over 90 languages to measure disease severity and quality of life.
Get the DLQI
To express the severity of psoriasis by measuring redness, thickness, and scaliness of the lesions, weighed by the area of involvement.
Get the PASI
PGA: Physician's Global Assessment
Physician's assessment of the severity of disease based on a scale from clear to very severe.
Get the PGA
Self-administered, patient-reported outcome measure (PRO) to assess symptom severity in chronic, plaque psoriasis.
Learn more
A 10-question questionnaire based on the experiences of children with skin disease. Available in both a text-only version as well as The Cartoon CDLQI, with each question illustrated by a cartoon based on the theme of the question, catering to younger children.
Get the CDLQI
PEST is a validated screening tool for psoriatic arthritis (PsA) and it is recommended that patients with psoriasis who do not have a diagnosis of PsA complete an annual PEST questionnaire (NICE psoriasis guidelines 2012). A score of 3 or more indicates referral to rheumatology should be considered.
Get the PEST
A clinical outcome measure for the assessment of genital psoriasis severity that accounts for the erythematous clinical presentation of genital psoriasis
IPC does not endorse or accept any responsibility for the content of external websites.
congress coverage EADV 2019 Read the psoriasis highlights from the EADV 2019 congress learn more
Latest news Commentary: The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologicsMay 28, 2020Searching for signals of increased risk of infection in specific subgroups is vitally important, especially when confronted with a severe threat to health, like the worldwide spread of the SARS-CoV-2 virus. Stories from the Field: COVID-19 and Psoriatic ArthritisMay 27, 2020US-based rheumatologist and IPC Councilor Arthur Kavanaugh, MD, discusses his plans to continue offering telemedicine appointments to patients after the pandemic. "Telemedicine is a new skill set that [we] providers need to learn," says Dr. Kavanaugh in this week's Stories from the Field video. Translations NOW AVAILABLE: January 2020 Psoriasis Review NewsletterMay 26, 2020 Stories from the Field: Impact of COVID-19 restrictions on psoriasis patients in EgyptMay 20, 2020Due to COVID-19 restrictions, patients in Egypt with severe psoriasis are not getting timely access to biologic treatment. IPC Board Member Mahira Hamdy El Sayed, MSc, MD, discusses the potential fallout for Egyptians with psoriasis, post-COVID-19. More News